Suckling Science Ltd, 291 Knightsfield, Welwyn Garden City, Herts, AL8 7NH, UK.
Expert Opin Ther Pat. 2012 Mar;22(3):199-204. doi: 10.1517/13543776.2012.667402. Epub 2012 Mar 9.
This paper is an update of a previous paper I published in Expert Opinion of Therapeutic Patents in 2008. The paper was a survey of patenting activity in the fields of atherosclerosis and dyslipidaemia, which identified trends in patenting by reviewing two major mechanistic categories, metabolic/dyslipidaemia and vascular/inflammation, as well as examining the interest in certain specific targets over a period of 10 years.
In this update, the same methodology was followed using the Espacenet of the European Patent Office (EPO) to identify patents claiming therapeutics for atherosclerosis or dyslipidaemia (excluding the wider metabolic syndrome).
A major change in the field over the past 5 years has been the departure of larger companies from the field. This is reflected in the patenting activity. Patenting has been at a stable rate over the recent years with few new targets being highlighted. It is suggested that, for this field to return to the higher rates of patenting seen over 10 years ago, breakthroughs in translational medicine and in the ability to conduct clinical trials, particularly in biomarkers and imaging, will need to take place.
本文是我 2008 年在《治疗专利专家意见》上发表的一篇论文的更新。该论文对动脉粥样硬化和血脂异常领域的专利活动进行了调查，通过审查两种主要的机制类别——代谢/血脂异常和血管/炎症，以及在 10 年的时间内检查某些特定靶点的兴趣，确定了专利申请的趋势。
在本次更新中，使用欧洲专利局（EPO）的 Espacenet 采用相同的方法，以确定声称治疗动脉粥样硬化或血脂异常（不包括更广泛的代谢综合征）的疗法的专利。
过去 5 年来，该领域的一个重大变化是较大的公司已退出该领域。这反映在专利活动中。近年来，专利申请率一直保持稳定，很少有新的靶点被突出。有人建议，为了使该领域恢复到 10 多年前的更高专利申请率，需要在转化医学和进行临床试验的能力方面取得突破，特别是在生物标志物和影像学方面。
